Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Empagliflozin/Linagliptin vs Glyxambi
NCT05956522Phase 1Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jul 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin and linagliptin in type 2 diabetes mellitus (T2DM), sponsored by The Affiliated Hospital of Qingdao University. Started Jul 2022; status: completed.
02
Drugs
empagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05956522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05956522.